Premium
Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone
Author(s) -
Roffeei Siti Norsyuhada,
Reynolds Gavin P.,
Zainal Nor Zuraida,
Said Mas Ayu,
Hatim Ahmad,
Aida Syarinaz Ahmad,
Mohamed Zahurin
Publication year - 2014
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.2366
Subject(s) - ziprasidone , aripiprazole , methylenetetrahydrofolate reductase , medicine , antipsychotic , allele , genotype , body mass index , pharmacology , endocrinology , schizophrenia (object oriented programming) , gastroenterology , genetics , psychiatry , gene , biology
Objectives Various genetic polymorphisms have been reported to be associated with antipsychotic‐induced weight gain. In this study, we aimed to determine whether risk polymorphisms in 12 candidate genes are associated with reduction in body mass index (BMI) of patients following switching of antipsychotics to aripiprazole or ziprasidone. Methods We recruited 115 schizophrenia patients with metabolic abnormalities and who have been on at least 1 year treatment with other antipsychotics; they were then switched to either aripiprazole or ziprasidone. They were genotyped, and their BMI monitored for 6 months. Results S ignificant associations with reduction in BMI at 6 months following switching were found in two of these genes: with rs1800544 of the ADRA2A gene (CC + CG [−0.32 ± 1.41 kg/m 2 ] vs GG [−1.04 ± 1.63 kg/m 2 ], p = 0.013) and with rs1801131 of the MTHFR gene (AA [−0.36 ± 1.53] vs AC + CC [−1.07 ± 1.53], p = 0.015). Conclusion The study data indicated that carriage of the ADRA2A rs1800544 GG genotype and the MTHFR rs1801131 C allele are associated with BMI reduction in this population following switching of antipsychotics to aripiprazole and ziprasidone. Copyright © 2013 John Wiley & Sons, Ltd.